Trial Profile

Effect of anakinra (soluble interleukin - 1 receptor antagonist) as combination therapy: second UK combination therapy in early rheumatoid arthritis.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Methotrexate
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms CARDERA-2

Most Recent Events

02 Feb 2016 Results published in the Clinical and Experimental Rheumatology
01 Jan 2010 New source identified and integrated (ISRCTN: Current Controlled Trials).
13 May 2009 UKCRN reports end date as 31 Dec 2007.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com